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Aims The identification of responders to cardiac resynchronization therapy (CRT) remains a challenge. We assessed the
role of dyssynchrony (DYS) and contractile reserve (CR) in identifying CRT responders.
Methods
and results
Sixty-nine patients (55% with ischaemic aetiology) referred for CRT (ejection fraction 35%, New York Heart
Association III, and QRS duration 120 ms) underwent baseline evaluation of DYS and dobutamine stress-echo
[up to 40 mg/kg/min: CR was defined as a wall motion score index (WMSI) variation 0.20]. CRT responders
were identified by clinical and/or echocardiographic [end-systolic volume (ESV) decrease 15%] follow-up criteria.
During a median follow-up of 11 months, 46 patients (66%) were classified as clinical responders. Reverse remodel-
ling was found in 34 of the 59 patients (58%) with echocardiographic follow-up. CR was present in 78% of clinical
responders (P ¼ 0.001) and in 69% with reverse remodelling (P ¼ 0.005). DYS was equally present in the two
groups. Reverse remodelling was correlated with rest–stress changes in ESV (r ¼ 0.439, P ¼ 0.003) and in WMSI
(r ¼ 0.450, P ¼ 0.001), but not with DYS. CR (OR ¼ 6.2, 95% CI ¼ 1.4–27.6, P ¼ 0.015) was the best predictor
of response to CRT.
Conclusion Patients with CR show a favourable clinical and reverse LV remodelling response to CRT. This finding shifts the focus
from electrical (dyssynchrony) to the myocardial substrate of functional response.
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Introduction
Ventricular dyssynchrony appears to have a deleterious impact on
the natural history of heart failure (HF), as a wide QRS complex
has been associated with increased mortality in patients experien-
cing HF.1,2 Despite major advances in medical therapy, morbidity
and mortality in HF remain high.3 Cardiac resynchronization
therapy (CRT) was introduced in the mid-1990s, and has devel-
oped dramatically over time.4 CRT was approved by the Food
and Drug Administration in 2001 and was classified in the ESC
guidelines for cardiac pacing and CRT with Level of Evidence
IA.5 CRT is increasingly used in patients with HF, but the identifi-
cation of ‘responders’ remains challenging, since up to one in three
patients do not show symptomatic improvement with this costly
and demanding electrical therapy.6 QRS width remains to be the
single established criterion to assess intraventricular dyssynchrony
according to guidelines; however, there is no accepted consensus
on which imaging parameter is best to predict CRT response.
Promising but somewhat inconsistent results have been obtained
with several indices of left ventricular (LV) dyssynchrony,7,8 and
more recently with myocardial viability.9,10 Functional dyssyn-
chrony and anatomic scar assess conceptually different variables,
and it is not clear at present whether they offer clinically redundant
or additive information for predicting response to CRT. Echocar-
diography can offer insights into LV dyssynchrony, for instance
with tissue Doppler imaging, and LV viability, which is mirrored
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by the presence of contractile reserve (CR) by dobutamine stress
echo.11
The aim of this study was therefore to assess the value of intra-
ventricular dyssynchrony at rest and stress echo myocardial CR,
for identifying responders to CRT.
Methods
Study patients
This was a prospective, multicentre study, conducted in Italy between
2004 and 2007. Patients were enrolled at three centres; the Cardiology
Division, Benevento (n ¼ 37), the Institute of Clinical Physiology,
National Council of Research (n ¼ 36), and Cardiology Division,
Vallo della Lucania (n ¼ 6). The study population consisted of patients
with HF referred for CRT, who met the following criteria: (i) severe
HF with New York Heart Association (NYHA) functional class III;
(ii) global LV dysfunction (ejection fraction 35% by biplane area
length method on resting echocardiogram); (iii) wide QRS complex
with duration .120 ms.5 All patients were required to have an ade-
quate transthoracic echocardiogram from which resting regional wall
function could be assessed (the echocardiogram was considered ade-
quate if .13 of the maximum 17 segments were visualized in at least
one projection). Exclusion criteria were: (i) technically poor acoustic
window precluding satisfactory imaging of the LV (for two-dimensional
echo); (ii) haemodynamic instability; (iii) documentation of life-
threatening ventricular arrhythmias (sustained ventricular tachycardia
or ventricular fibrillation); (iv) significant co-morbidity reducing life-
expectancy to ,1 year, and (v) unwillingness to give informed
consent.
Of the 79 patients initially selected for the study, 10 patients were
subsequently excluded owing to inadequate echocardiographic image
quality during stress because of inadequate wall motion analysis.
Thus, 69 patients were included in the final study group. The study
was approved by the relevant Institutional Review Board. All patients
gave their written informed consent prior to undergoing stress echo-
cardiography. When patients signed the written informed consent
they also authorized physicians to use their clinical data according to
Italian Law.
Sixty-five patients were in normal sinus rhythm and four in atrial
fibrillation. All patients were on optimal and maximally tolerated
pharmacological therapy, according to current guidelines for treatment
of HF.12 Thirty-eight patients (55%) had ischaemic heart disease: pre-
vious inferior and infero-lateral myocardial infarction in 16 (42%) and
previous anterior and apical myocardial infarction in 22 patients
(58%). All patients with ischaemic cardiomyopathy had undergone a
previous revascularization procedure, 18 by percutaneous coronary
intervention and 20 by coronary artery bypass grafting. No patients
with ischaemic cardiomyopathy had a positive test for myocardial
ischaemia during dobutamine stress echocardiography, and no patients
showed viability in the segments with akinesia during stress echocar-
diography. Coronary angiography was performed in all patients and
none of the patients had a coronary anatomy suitable for further
revascularization.
Clinical information was recorded on the case report form at study
entry by the accredited cardiologist/echocardiographer at each centre.
Resting and stress echocardiography was performed in each of the
three recruiting centres by cardiologists-sonographers accredited by
the European Association of Echocardiography, who had passed the
training course and quality control reading test of the stress echocar-
diography multi-centre trial network.13,14 Images were coded and read
in the core laboratory by observers blinded to clinical conditions and
follow-up data. All measurements were obtained following the rec-
ommendations of the American Society of Echocardiography15 at
baseline and during follow-up. In particular, LV volumes and ejection
fraction were assessed from two-dimensional, two- and four-chamber
views by biplane area.
Stress echocardiography protocol
All patients underwent high-dose dobutamine stress echocardiogra-
phy. Dobutamine was infused in 3 min dose increments, starting at
5 mg/kg/min and increasing to 10, 20, 30, and 40 mg/kg/min. Wall
Motion Score Index (WMSI, defined as 1 ¼ normal to 4 ¼ dyskinetic
in a 17-segment model of the LV) was assessed following the rec-
ommendations of the American Society of Echocardiography and
European Association of Echocardiography.15,16 A stress test was con-
sidered maximal when the highest dose of dobutamine was reached.
The infusion was discontinued before the maximal dose was reached
if 85% of the maximal predicted heart rate for the age group was
achieved, or symptomatic non-sustained or sustained ventricular tachy-
cardia was observed.
Ongoing medical therapy (including b-blockers) was kept unchanged
at the time of the stress test. CR was defined as a delta variation of
(rest–stress) 0.20 in WMSI.17,18 We also measured LV end-diastolic
(EDV) and end-systolic volumes (ESV) at baseline and peak stress.
Intraventricular dyssynchrony
Tissue Doppler was performed in 55 of the 69 patients. Gain and
filters were adjusted as needed to eliminate background noise and
to allow for a clear tissue signal. The tissue Doppler signals were
recorded at a sweep speed of 100 mm/s. From the apical four- and
two-chamber view, a 5 mm sample volume was placed in the LV
basal portions of the lateral and septal, inferior and anterior walls.
Intraventricular dyssynchrony was calculated by off-line analysis of
pulsed wave Doppler as the maximal difference in time intervals
between the onset of the QRS complex and the peak mitral annulus
systolic velocities of the four ventricular segments.7,19 Measurements
were made between three to five cardiac cycles and averaged.
Cardiac resynchronization therapy
implantation
A coronary sinus venogram was obtained using a balloon catheter, fol-
lowed by insertion of the LV pacing lead. The LV pacing lead was
inserted transvenously via the subclavian route. An 8F guiding catheter
was used to position the LV lead in the coronary sinus. The preferred
position was a lateral or posterolateral vein. The right atrial and ven-
tricular leads were positioned conventionally. All leads were con-
nected to a dual-chamber biventricular pacemaker or an internal
defibrillator. At implantation, both the sensing and pacing thresholds
(at pulse duration of 0.5 ms) of the LV pacing lead were measured.
The final position of the LV pacing lead was assessed with cine fluoro-
scopy. CRT devices were optimized for atrioventricular (AV) and
interventricular (VV) delays after CRT.
Follow-up data
Follow-up data were obtained from at least one of the following four
sources: review of the patient’s hospital records, personal communi-
cation with the patient’s physician and review of the patient’s chart,
a telephone interview with the patient conducted by trained person-
nel, a staff physician seeing the patient at regular intervals in the out-
patient clinic. Clinical follow-up data were obtained in all patients.
Events were defined as all-cause death, cardiac death, and
Q. Ciampi et al.Page 2 of 8
development or progression of HF. For patients who died in-hospital
or at home, the cause of death was elucidated from the medical
record, the family, and the local physician who signed the death certi-
ficate. The definition of cardiac death required documentation of sig-
nificant arrhythmias or cardiac arrest, or both; or death attributable
to congestive HF or myocardial infarction in the absence of any
other precipitating factors. In case of deaths out of hospital for
which no autopsy was performed, sudden unexpected death was
attributed to a cardiac cause. The development or progression of
HF was defined as at least one of the following: worsening of functional
class to NYHA class III and IV, new hospitalization for HF, or heart
transplantation. Therefore, the outcome events were all-cause death
(defined as cardiac and non-cardiac death) for survival, and spon-
taneous events (death and the development or progression of HF)
for spontaneous event-free survival. When more than one of these
events occurred, the patient was censored at the time of the most
severe event. According to the study protocol follow-up information
were obtained every 6 months.
Clinical responders were defined as survivors who had a 1 grade
improvement in NYHA class, and no new hospital admission for acute
HF. Echocardiographic responders were defined as patients who
showed LV reverse remodelling, defined as a decrease in LV ESV of
15% at 6 months follow-up, compared with the baseline value
before CRT.7,20
Statistics
Data are expressed as mean+ standard deviation for continuous vari-
ables and as numbers (%) for categorical variables. The individual effect
of variables on event-free survival was evaluated with a Cox regression
model. The analysis was performed according to an unmodified,
forward-selection, stepwise procedure. In this analysis, variables
were entered into the model on the basis of a computed significance
probability; accordingly, the variable that seemed to have the most sig-
nificant relationship with the dependent outcome was selected for
inclusion in the model, and a solution to the functional form of
equation was computed. The remaining variables were evaluated suc-
cessively, and the most significant were included if they seemed to
improve the outcome prediction (dependent variable). In this case
the probability was dependent on the presence of the variables,
which were already selected. The algorithm ceases to select variables
when there is no further significant improvement in the prediction of
the whole model. The variables selected for examination were age,
NYHA class, history of ischaemic cardiomyopathy, QRS duration, LV
EDV and LV ESV diameters, LV EDV and LV ESV, ejection fraction at
rest and at peak stress, WMSI at rest and peak of stress, high-dose
rest–stress wall motion index variation (DWMSI). Continuous vari-
ables were compared by paired-samples t-test. Proportions were com-
pared by x2 statistics. Fisher’s exact test was used when appropriate.
Clinical event curves were analysed using the Kaplan–Meier method.
Bland–Altman analysis was performed to evaluate interobserver varia-
bility of LV ESVs in a subset of 10 randomly selected patients.
A probability value of ,0.05 was considered statistically significant.
All statistical calculations were performed using SPSS for Windows,
release 12.0 (Chicago, IL, USA).
Results
Patient characteristics
Sixty-nine patients were enrolled (49 males, mean age 70+8
years). The baseline clinical and echocardiographic characteristics
of the patients are summarized in Table 1. All patients received
optimized medical therapy for at least 8 weeks if tolerated.
Device implantation was successful in all patients and no
procedure-related complications were observed. One patient
was admitted for LV lead repositioning during follow-up, because
of LV dislocation resulting in non-capture.
Feasibility and tolerability of high-dose
dobutamine stress echocardiography
All patients reached the maximal dose of dobutamine during stress
echocardiography (up to 40 mg/kg/min). During dobutamine infu-
sion, non-sustained ventricular tachycardia was observed in nine
patients (13%) and hypotension in one patient (1%). These types
of complications were always well-tolerated and did not cause pre-
mature interruption of the test. Technically adequate images were
obtained for all patients at baseline and during the stress test.
Haemodynamic and echocardiographic responses to dobutamine
stress are described in Table 2. A CR (defined as WMSI variation
0.20 between rest and peak stress) was found in 45 patients
(65%). Interobserver variability in the measurement of LV ESVs
by the two independent sonographers showed excellent corre-
lation (r ¼ 0.89, P, 0.01) with no significant difference at rest
(0.7+22 mL, 95% confidence interval: 243.7 to 45.2 mL, P ¼
0.8) or peak stress (5.4+12 mL, 95% confidence interval:
219.4 to 30.2 mL, P ¼ 0.4).
Clinical follow-up
All patients completed the clinical follow-up with median duration
of 11 months. Forty-six patients (66%) were classified as clinical
responders to CRT and 23 patients (34%) as clinical non-
responders: eight deaths (11%), 12 acute HF (17%), and three
unchanged NYHA class (4%). The characteristics of the clinical
Table 1 Clinical and baseline echocardiographic
characteristics (n 5 69)
Age (years) 70+8
Males, n (%) 49 (71)
New York Heart Association functional class (III/IV) 57/12
Ischaemic heart disease, n (%) 38 (55)
QRS complex duration (ms) 150+27
Left ventricular end-diastolic diameter (mm) 66+6
Left ventricular end-systolic diameter (mm) 56+7
Left ventricular end-diastolic volume (mL) 176+64
Left ventricular end-systolic volume (mL) 129+52
Left ventricular ejection fraction (%) 27+6
Mitral regurgitation (moderate to severe), n (%) 26 (38)
Restrictive transmitral pattern, n (%) 12 (20)
Intraventricular dyssynchrony (ms) 81+39
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responders and non-responders were comparable at rest, but
there was a significant difference in myocardial CR, evaluated
during stress echocardiography, in the two patient groups
(Table 3).
By log-rank analysis, event-free survival was also significantly
better in patients with CR than in the group without CR
(log-rank ¼ 4.26, P ¼ 0.039; Figure 1).
Left ventricular reverse remodelling
during follow-up
Fifty-nine patients (85%) completed the echocardiographic
follow-up. LV reverse remodelling (LV ESV decrease 15% at
follow-up) was found in 34 patients (58%). The characteristics of
the patients with and without reverse remodelling are shown in
Table 4. At rest, patients with LV reverse remodelling had a
thicker interventricular septum, higher E-wave deceleration time,
and a significantly higher myocardial CR compared with patients
without LV reverse remodelling.
LV reverse remodelling was correlated with pre-CRT
rest–stress changes in ESV (r ¼ 0.439, P ¼ 0.003) and in WMSI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Characteristics of clinical responders and non-responders
Clinical responders (n5 46) Clinical non-responders (n 5 23) P-value
Age (years) 68+9 70+6 N.S.
Ischaemic heart disease, n (%) 21 (46) 17 (74) N.S.
QRS complex duration (ms) 152+22 148+27 N.S.
Interventricular septum (mm) 10+2 10+2 N.S.
E-wave deceleration time (ms) 195+84 185+67 N.S.
LV ejection fraction at rest (%) 27+6 25+5 N.S.
Intraventricular dyssynchrony (ms) 76+35 81+52 N.S.
Dyssynchrony index (%) 29/38 (76%) 13/17 (76%) N.S.
DWMSI during SE (%) 0.42+0.28 0.17+0.19 ,0.001
Contractile reserve, n (%) 36 (78) 9 (39) 0.001
D, change between rest and stress echo (SE); WMSI, wall motion score index; LV, left ventricular.
Figure 1 Kaplan–Meier survival curves in patients after cardiac
resynchronization therapy, stratified according to the results of
rest–stress wall motion score index (WMSI) variation during
dobutamine stress echo. Event-free survival was better for
patients with a larger variation of WMSI (0.20).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Haemodynamic and echocardiographic responses to dobutamine stress
Rest Stress D (%) P-value
Heart rate (b.p.m.) 72+15 104+22 þ57+49 0.023
Systolic blood pressure (mmHg) 110+23 125+29 þ14+27 ,0.001
Double product 7900+1819 12 926+3631 þ66+39 ,0.001
End-diastolic volume (mL) 176+64 155+58 29+15 ,0.001
End-systolic volume (mL) 129+52 99+53 223+21 ,0.001
LV ejection fraction (%) 27+6 38+13% þ47+46 ,0.001
WMSI 2.33+0.29 1.99+0.43 20.33+0.28 ,0.001
WMSI, wall motion score index.
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(r ¼ 0.450, P ¼ 0.001). CR was correlated with change in WMSI at
follow-up (r ¼ 20.661, P, 0.001).
Ischaemic vs. non-ischaemic
cardiomyopathy
Thirty-eight HF patients (55%) showed an ischaemic aetiology.
During dobutamine stress echocardiography none of the patients
with ischaemic cardiomyopathy showed an ischaemic or biphasic
response. In fact, coronary artery angiography excluded suitability
for further revascularization. Moreover, patients with ischaemic
cardiomyopathy had a similar ejection fraction at rest (26+ 4%
vs. 27+ 7%, P ¼ N.S.), ESV at rest (127+43 mL vs. 133+
61 mL, P ¼ N.S.), and WMSI at rest (2.09+0.3 vs. 1.88+0.5,
P ¼ N.S.) compared with patients without ischaemic cardiomyopa-
thy. In addition, there was no difference during dobutamine stress
echocardiography in: ejection fraction at peak (38+ 10% vs. 38+
15%, P ¼ N.S.), ESV at peak (94+37 mL vs. 104+ 67 mL, P ¼
N.S.), difference in WMSI between rest and stress (0.27+ 0.2 vs.
0.4+ 0.3, P ¼ N.S.), and presence of myocardial CR (63% vs.
71%, P ¼ N.S.), between these two groups. There was a similar
incidence of clinical responders (Table 3) and echocardiographic




Fifty-five HF patients underwent analysis of intraventricular dyssyn-
chrony and echocardiographic follow-up. Figure 2 shows the per-
centage of CRT responders for four different patient categories
based on the presence or absence of myocardial CR in combi-
nation with the presence or absence of intraventricular tissue
Doppler dyssynchrony (65 ms). On individual patient analysis,
myocardial CR was more often associated with a favourable
outcome, whereas dyssynchrony criteria were equally present in
the two groups (Figure 2). On multivariate analysis, in the 55 HF
patients with intraventricular dyssynchrony and echocardiographic
follow-up, the presence of myocardial CR (OR ¼ 6.2, 95% CI ¼
1.4–27.6, P ¼ 0.015) was the best predictor of clinical and echo-
cardiographic response to CRT, regardless of the presence of
wide QRS and tissue Doppler intraventricular dyssynchrony.
Discussion
In this study, we have demonstrated that patients with CR during
stress echocardiography show a favourable clinical and echocardio-
graphic response to CRT. In fact, the presence of CR was related
to better event-free survival, with an inverse relationship between
CR and reverse remodelling, while the ECG and echocardiographic
dyssynchrony criteria were equally present in clinical and echocar-
diographic responders and non-responders.
Figure 2 Percentages of responders to cardiac resynchroniza-
tion therapy for four different patient categories based on the
presence or absence of contractile reserve (CRþ/CR2) in com-
bination with the presence or absence of baseline tissue Doppler
criteria of intraventricular dyssynchrony (DYSþ/DYS2).
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Table 4 Characteristics of echocardiographic responders and non-responders
Reverse remodelling (n 5 34) No reverse remodelling (n5 25) P-value
Age (years) 69+8 69+8 N.S.
Ischaemic heart disease, n (%) 14 (42) 16 (64) N.S.
QRS complex duration (ms) 150+27 150+29 N.S.
Interventricular septum (mm) 11+2 9+2 ,0.001
E-wave deceleration time (ms) 215+83 161+66 0.015
LV ejection fraction at rest (%) 27+6 27+6 N.S.
Intraventricular dyssynchrony (ms) 74+34 91+49 N.S.
Dyssynchrony index (%) 22/29 (76%) 14/20 (70%) N.S.
DWMSI during SE (%) 0.43+0.30 0.25+0.23 0.015
Contractile reserve, n (%) 29 (85) 13 (52) 0.005
D, change between rest and stress echo (SE); WMSI, wall motion score index; LV, left ventricular.
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Intraventricular dyssynchrony and the
uncertain prediction of cardiac
resynchronization therapy response
Several echocardiographic techniques have been used to assess
intraventricular dyssynchrony; however, tissue Doppler is the
most extensively tested technique.5,6 Promising but somewhat
inconsistent results have been obtained with several indices of
LV dyssynchrony. The results of the PROSPECT study showed
that no single echocardiographic measure of dyssynchrony was
reliable and ready for widespread use in the selection of candi-
dates for CRT.21 Indeed, recent ESC guidelines for cardiac
pacing and HF do not suggest specific echocardiographic dyssyn-
chrony criteria, and at present, QRS width remains to be the
ventricular dyssynchrony criterion to identify HF patients suit-
able for CRT.5 In accordance with this evidence, in our multi-
centre study we found that tissue Doppler intraventricular
dyssynchrony was equally present in clinical and echocardio-
graphic responders and non-responders to CRT (Tables 3 and
4). In addition, on multivariate analysis, wide QRS and tissue
Doppler intraventricular dyssynchrony did not predict the
response to CRT.
Myocardial viability predicts response to
cardiac resynchronization therapy
In patients with depressed ejection fraction (,35%), the identifi-
cation of CR during dobutamine stress echocardiography has
been shown to provide important prognostic information22 in
revascularized ischaemic cardiomyopathy,23 as well as in non-
ischaemic cardiomyopathy patients on medical therapy,18,24 and
in low-flow, low-gradient severe aortic stenosis patients under-
going valve replacement.25
More specifically, in patients with dilated cardiomyopathy
referred for CRT, Da Costa et al.26 observed that the presence
of myocardial CR was an independent predictor of event-free sur-
vival after CRT. CR is a specific marker of underlying myocardial
viability, which can also be assessed with similar accuracy by
nuclear medicine and cardiac magnetic resonance techniques.27,28
These techniques also showed that the extent of viable myocar-
dium and/or transmural scar tissue play an important role in iden-
tifying responders to CRT.9,10,29 –32
Study limitations
We assessed wall motion score index in a standard, eyeballing,
semi-quantitative manner,15 as recommended by the most
recent guidelines of the American Society of Echocardiography
and European Association of Echocardiography.16 Wall motion
is subject to variability,33 particularly in HF patients owing to pre-
existing wall motion abnormalities and the substantial number of
patients with left bundle branch block; for this reason images
were coded and read in the core laboratory, as recommended
by the American Society of Echocardiography for use of stress
echocardiography in clinical trials.34 The sonographers acquiring
the stress echocardiography data in each of the three recruiting
centres had all passed the accreditation process on stress echo-
cardiography reading, as previously described,13 to ensure consist-
ency in acquisition, segmentation, and execution. The core
laboratory reader was also accredited by the European Associ-
ation of Echocardiography. The inherent variability and subjectiv-
ity of the stress echocardiography reading was therefore
minimized in this study.35
In the present study we did not analyse either AV or VV dys-
synchrony, in addition, VV dyssynchrony was only assessed in 55
patients. This is a potential limitation of the study and may have
lowered the power of stratification in this set of patients. This
reflects the wide deregulation and continuous update of pro-
posed dyssynchrony criteria, with different waves and fashions
in the echocardiography laboratory.36 We shifted at a certain
time from M-mode-based to tissue Doppler-based criteria,
which held the promise of greater feasibility, reproducibility,
and accuracy. Speckle tracking strain analysis is a novel
method that permits the assessment of myocardial deformation
in two dimensions; the role of a strain delay index by speckle
tracking for the prediction of response to CRT in both
ischaemic and non-ischaemic patients has been recently
demonstrated.37
We used a high-dose protocol for dobutamine stress echocar-
diography, without atropine administration. The high-dose plus
atropine protocol is currently recommended by the American
Society of Echocardiography and European Association of Echo-
cardiography for dobutamine stress testing for the diagnosis of cor-
onary artery disease.33 We decided to use the high dose of
dobutamine, but to avoid the use of atropine. The high dobutamine
dose is particularly advisable in our patients, who were mostly on
b-blockers at the time of testing (which may determine a rightward
shift in the dobutamine dose-contractile response curve). In
addition, our patients have b-adrenoreceptor downregulation as
a part of their adaptation to HF. Lower doses would have been
inadequate to elicit a full contractile response, and higher doses
with atropine co-administration might have been unsafe in patients
with depressed resting function. Even without atropine
co-administration, we observed significant arrhythmias in over
10% of our population.
Finally, we assessed volume changes of the LV in two dimen-
sions, both at stress and during follow-up studies. Two-dimensional
study recognizes limitations in distorted and dilated LVs, because of
the need for geometric modelling and the errors caused by fore-
shortened views. A real-time three-dimensional technique would
have been more accurate for volume calculations at baseline and
during stress. However, the two-dimensional approach, which
was the only one available to recruiting centres at the time of
study design, provides consistent information especially when
each patient acts as his/her own control, during stress and at
serial follow-up examinations.15
Conclusion
Patients with CR during stress echocardiography show a favourable
clinical and reverse LV remodelling response to CRT. This finding
shifts the focus from electrical (dyssynchrony) to the myocardial
substrate of functional response. The use of dobutamine stress
echocardiography has obvious potential for a better selection of
CRT candidates, although larger studies are clearly needed at
this point.
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